Novel serum tumor marker, RCAS1, in pancreatic diseases
AIM： As tumor markers for pancreatic carcinoma, carcinoembryonic antigen （CEA） and carbohydrate antigen （CA） 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS： A novel serum tumor marker, RCAS1, was compared with two convention...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2005-09, Vol.11 (33), p.5199-5202 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5202 |
|---|---|
| container_issue | 33 |
| container_start_page | 5199 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 11 |
| creator | Yamaguchi, Koji Enjoji, Munechika Nakashima, Manabu Nakamuta, Makoto Watanabe, Takashi Tanaka, Masao |
| description | AIM： As tumor markers for pancreatic carcinoma, carcinoembryonic antigen （CEA） and carbohydrate antigen （CA） 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS： A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA （highly specific for pancreatic cancer） and CA 19-9 （highly sensitive for pancreatic cancer）, in 48 patients with pancreatic exocrine tumors. RESULTS： When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone （55%） was higher than that of CEA alone （27%） and the specificity of RCAS1 alone （92%） was greater than that of CA19-9 alone （78%）. When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 （95%） was superior to those of CA19-9 alone （78%）, RCAS1 alone （55%, P = 0.002）, CEA alone （27%） （P〈0.001）, RCAS1 and CEA （59%） and CA19-9 and CEA （82%）. CONCLUSION： These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma. |
| doi_str_mv | 10.3748/wjg.v11.i33.5199 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4320395</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>20138217</cqvip_id><wanfj_id>wjg200533017</wanfj_id><sourcerecordid>wjg200533017</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-dbb3a2cbf7fd49c9c128d81d0f63b549a0e1ec905889fcc00c72cb5ed7b391113</originalsourceid><addsrcrecordid>eNpVkEtLAzEUhYMotj72rmQQcdWpucmkmWyEUnyBKPhYh0wmU9POZNpkpuK_N1AVXd3F_Tjf4SB0AnhMeZZffizm4w3A2FI6ZiDEDhoSAiIleYZ30RAw5qmghA_QQQgLjAmljOyjAUyAcM7IEPHHdmPqJBjfN0nXN61PGuWXxo-S59n0BUaJdclKOe2N6qxOShuMCiYcob1K1cEcf99D9HZz_Tq7Sx-ebu9n04dUU4K7tCwKqoguKl6VmdBCA8nLHEpcTWjBMqGwAaMFZnkuKq0x1jzSzJS8oAIA6CG62uau-qIxpTau86qWK29jzU_ZKiv_f5x9l_N2I7Pop4LFgPNtwIdylXJzuWh772JlGccjGDNKMfCIXXx7fLvuTehkY4M2da2cafsgJzmLyxISwdO_hX6b_EwagbMtoN9bN1_bqCyUXla2NpJgoDmJui8NtYQv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68522122</pqid></control><display><type>article</type><title>Novel serum tumor marker, RCAS1, in pancreatic diseases</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yamaguchi, Koji ; Enjoji, Munechika ; Nakashima, Manabu ; Nakamuta, Makoto ; Watanabe, Takashi ; Tanaka, Masao</creator><creatorcontrib>Yamaguchi, Koji ; Enjoji, Munechika ; Nakashima, Manabu ; Nakamuta, Makoto ; Watanabe, Takashi ; Tanaka, Masao</creatorcontrib><description>AIM： As tumor markers for pancreatic carcinoma, carcinoembryonic antigen （CEA） and carbohydrate antigen （CA） 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS： A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA （highly specific for pancreatic cancer） and CA 19-9 （highly sensitive for pancreatic cancer）, in 48 patients with pancreatic exocrine tumors. RESULTS： When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone （55%） was higher than that of CEA alone （27%） and the specificity of RCAS1 alone （92%） was greater than that of CA19-9 alone （78%）. When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 （95%） was superior to those of CA19-9 alone （78%）, RCAS1 alone （55%, P = 0.002）, CEA alone （27%） （P〈0.001）, RCAS1 and CEA （59%） and CA19-9 and CEA （82%）. CONCLUSION： These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v11.i33.5199</identifier><identifier>PMID: 16127752</identifier><language>eng</language><publisher>United States: Department of Surgery and Oncology,Graduate School of Medicine,Kyushu University,Japan%Medicine Bioregulatory Sciences,Graduate School of Medical Sciences,Kyushu University,Japan%Department of Molecular Immunology,Medical Institute of Bioregulation,Faculty of Medicine,Kyushu University,Japan</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm - blood ; Biomarkers, Tumor - blood ; Brief Reports ; CA-19-9 Antigen - blood ; Female ; Humans ; Male ; Middle Aged ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - diagnosis ; RCAS1 ; Sensitivity and Specificity ; 病理机制 ; 肿瘤标记物 ; 胰腺癌</subject><ispartof>World journal of gastroenterology : WJG, 2005-09, Vol.11 (33), p.5199-5202</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>The Author(s) 2005. Published by Baishideng Publishing Group Inc. All rights reserved. 2005</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320395/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320395/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16127752$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamaguchi, Koji</creatorcontrib><creatorcontrib>Enjoji, Munechika</creatorcontrib><creatorcontrib>Nakashima, Manabu</creatorcontrib><creatorcontrib>Nakamuta, Makoto</creatorcontrib><creatorcontrib>Watanabe, Takashi</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><title>Novel serum tumor marker, RCAS1, in pancreatic diseases</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>AIM： As tumor markers for pancreatic carcinoma, carcinoembryonic antigen （CEA） and carbohydrate antigen （CA） 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS： A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA （highly specific for pancreatic cancer） and CA 19-9 （highly sensitive for pancreatic cancer）, in 48 patients with pancreatic exocrine tumors. RESULTS： When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone （55%） was higher than that of CEA alone （27%） and the specificity of RCAS1 alone （92%） was greater than that of CA19-9 alone （78%）. When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 （95%） was superior to those of CA19-9 alone （78%）, RCAS1 alone （55%, P = 0.002）, CEA alone （27%） （P〈0.001）, RCAS1 and CEA （59%） and CA19-9 and CEA （82%）. CONCLUSION： These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, Neoplasm - blood</subject><subject>Biomarkers, Tumor - blood</subject><subject>Brief Reports</subject><subject>CA-19-9 Antigen - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>RCAS1</subject><subject>Sensitivity and Specificity</subject><subject>病理机制</subject><subject>肿瘤标记物</subject><subject>胰腺癌</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkEtLAzEUhYMotj72rmQQcdWpucmkmWyEUnyBKPhYh0wmU9POZNpkpuK_N1AVXd3F_Tjf4SB0AnhMeZZffizm4w3A2FI6ZiDEDhoSAiIleYZ30RAw5qmghA_QQQgLjAmljOyjAUyAcM7IEPHHdmPqJBjfN0nXN61PGuWXxo-S59n0BUaJdclKOe2N6qxOShuMCiYcob1K1cEcf99D9HZz_Tq7Sx-ebu9n04dUU4K7tCwKqoguKl6VmdBCA8nLHEpcTWjBMqGwAaMFZnkuKq0x1jzSzJS8oAIA6CG62uau-qIxpTau86qWK29jzU_ZKiv_f5x9l_N2I7Pop4LFgPNtwIdylXJzuWh772JlGccjGDNKMfCIXXx7fLvuTehkY4M2da2cafsgJzmLyxISwdO_hX6b_EwagbMtoN9bN1_bqCyUXla2NpJgoDmJui8NtYQv</recordid><startdate>20050907</startdate><enddate>20050907</enddate><creator>Yamaguchi, Koji</creator><creator>Enjoji, Munechika</creator><creator>Nakashima, Manabu</creator><creator>Nakamuta, Makoto</creator><creator>Watanabe, Takashi</creator><creator>Tanaka, Masao</creator><general>Department of Surgery and Oncology,Graduate School of Medicine,Kyushu University,Japan%Medicine Bioregulatory Sciences,Graduate School of Medical Sciences,Kyushu University,Japan%Department of Molecular Immunology,Medical Institute of Bioregulation,Faculty of Medicine,Kyushu University,Japan</general><general>Baishideng Publishing Group Inc</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20050907</creationdate><title>Novel serum tumor marker, RCAS1, in pancreatic diseases</title><author>Yamaguchi, Koji ; Enjoji, Munechika ; Nakashima, Manabu ; Nakamuta, Makoto ; Watanabe, Takashi ; Tanaka, Masao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-dbb3a2cbf7fd49c9c128d81d0f63b549a0e1ec905889fcc00c72cb5ed7b391113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, Neoplasm - blood</topic><topic>Biomarkers, Tumor - blood</topic><topic>Brief Reports</topic><topic>CA-19-9 Antigen - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>RCAS1</topic><topic>Sensitivity and Specificity</topic><topic>病理机制</topic><topic>肿瘤标记物</topic><topic>胰腺癌</topic><toplevel>online_resources</toplevel><creatorcontrib>Yamaguchi, Koji</creatorcontrib><creatorcontrib>Enjoji, Munechika</creatorcontrib><creatorcontrib>Nakashima, Manabu</creatorcontrib><creatorcontrib>Nakamuta, Makoto</creatorcontrib><creatorcontrib>Watanabe, Takashi</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamaguchi, Koji</au><au>Enjoji, Munechika</au><au>Nakashima, Manabu</au><au>Nakamuta, Makoto</au><au>Watanabe, Takashi</au><au>Tanaka, Masao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel serum tumor marker, RCAS1, in pancreatic diseases</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2005-09-07</date><risdate>2005</risdate><volume>11</volume><issue>33</issue><spage>5199</spage><epage>5202</epage><pages>5199-5202</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>AIM： As tumor markers for pancreatic carcinoma, carcinoembryonic antigen （CEA） and carbohydrate antigen （CA） 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS： A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA （highly specific for pancreatic cancer） and CA 19-9 （highly sensitive for pancreatic cancer）, in 48 patients with pancreatic exocrine tumors. RESULTS： When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone （55%） was higher than that of CEA alone （27%） and the specificity of RCAS1 alone （92%） was greater than that of CA19-9 alone （78%）. When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 （95%） was superior to those of CA19-9 alone （78%）, RCAS1 alone （55%, P = 0.002）, CEA alone （27%） （P〈0.001）, RCAS1 and CEA （59%） and CA19-9 and CEA （82%）. CONCLUSION： These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.</abstract><cop>United States</cop><pub>Department of Surgery and Oncology,Graduate School of Medicine,Kyushu University,Japan%Medicine Bioregulatory Sciences,Graduate School of Medical Sciences,Kyushu University,Japan%Department of Molecular Immunology,Medical Institute of Bioregulation,Faculty of Medicine,Kyushu University,Japan</pub><pmid>16127752</pmid><doi>10.3748/wjg.v11.i33.5199</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2005-09, Vol.11 (33), p.5199-5202 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4320395 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antigens, Neoplasm - blood Biomarkers, Tumor - blood Brief Reports CA-19-9 Antigen - blood Female Humans Male Middle Aged Pancreatic Neoplasms - blood Pancreatic Neoplasms - diagnosis RCAS1 Sensitivity and Specificity 病理机制 肿瘤标记物 胰腺癌 |
| title | Novel serum tumor marker, RCAS1, in pancreatic diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T16%3A36%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20serum%20tumor%20marker,%20RCAS1,%20in%20pancreatic%20diseases&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Yamaguchi,%20Koji&rft.date=2005-09-07&rft.volume=11&rft.issue=33&rft.spage=5199&rft.epage=5202&rft.pages=5199-5202&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v11.i33.5199&rft_dat=%3Cwanfang_jour_pubme%3Ewjg200533017%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68522122&rft_id=info:pmid/16127752&rft_cqvip_id=20138217&rft_wanfj_id=wjg200533017&rfr_iscdi=true |